



Viscera Labs Announces Receipt of Issue Notification from the USPTO

PARSIPPANY, NJ – November 22, 2022 – Viscera Labs, Inc. today announced that it had received an Issue Notification from the United States Patent and Trademark Office (USPTO) for its patent application on behalf of claims directed to a method of treating bile acid malabsorption diarrhea. The application will issue as U.S. Patent No. 11,524,029 on December 13, 2022.

Published studies suggest that bile acid sequestrants may have clinical utility in bile acid-mediated conditions such as bile acid malabsorption diarrhea¹. However, existing formulations of bile acid sequestrants are suboptimal and hence inadequate for these conditions. Viscera Labs is developing VL-001 to improve the efficacy, safety, and tolerability of colestevlam in bile acid-mediated conditions.

References

1. Beigel F, et al. Colesevelam for the treatment of bile acid malabsorption-associated diarrhea in patients with Crohn's disease: a randomized, double-blind, placebo-controlled study. *J Crohns Colitis*. 2014 Nov; 8(11): 1471-9.

About Viscera Labs

Viscera Labs is an innovative pharmaceutical company focused on developing novel and cost-effective therapeutic agents for bile acid-mediated disorders.